The rapidly evolving treatment landscape for patients with brain metastases from epidermal growth factor receptor mutated non-small cell lung cancer.

about

The rapidly evolving treatment landscape for patients with brain metastases from epidermal growth factor receptor mutated non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q47119162

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The rapidly evolving treatment ...... ed non-small cell lung cancer.

@en

The rapidly evolving treatment ...... ed non-small cell lung cancer.

@nl

type

Item

label

The rapidly evolving treatment ...... ed non-small cell lung cancer.

@en

The rapidly evolving treatment ...... ed non-small cell lung cancer.

@nl

prefLabel

The rapidly evolving treatment ...... ed non-small cell lung cancer.

@en

The rapidly evolving treatment ...... ed non-small cell lung cancer.

@nl

P1476

The rapidly evolving treatment ...... ed non-small cell lung cancer.

@en

P2093

Anthony M Brade

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferio

Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.

Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.

Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).

The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients.

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

P304

S55-S57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/TLCR.2017.10.14

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29299412

http://www.w3.org/2001/XMLSchema#string

P932

5750147

http://www.w3.org/2001/XMLSchema#string